Allergan plc Ordinary Shares (NYSE:AGN):
Allergan Reports Solid Top-Line Execution in Third Quarter 2017 with 11% Increase in GAAP Net Revenues to $4.03 Billion.
In the market the company is trading down by 0.79% percent from yesterday’s close.
Additionally Allergan plc Ordinary Shares recently announced a dividend for shareholders to be paid on Friday the 15th of December 2017. The dividend payment will be $0.700 per share for the quarter or $2.80 annualized. This dividend represents a yield of $1.57. The ex-dividend date is set for Wednesday the 16th of August 2017.
Allergan plc, launched on May 16, 2013, is a specialty pharmaceutical company. The Company is involved in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States. Within its US Specialized Therapeutics, US General Medicine and International operations, the Company sells its brand and aesthetic pharmaceutical products primarily to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail-order retailers, government agencies and managed healthcare providers, such as health maintenance organizations and other institutions..
Company shares last traded at $177.23 which is quite a bit lower than the 50 day moving average of $202.46 and well below the 200 day moving average of $227.37. The 50 day moving average was down $-25.23 or -12.46% and the 200 day average moved down $-50.14.
Allergan plc Ordinary Shares currently has a P/E ratio of 5.40 and market capitalization is 59.25B. In the latest earnings report the EPS was $32.82 and is expected to be $16.21 for the current year with 334,306,000 shares outstanding. Analysts expect next quarter’s EPS to be $4.77 and the next full year EPS is projected to be $16.85.
Traders are feeling more bullish on Allergan plc Ordinary Shares lately if you take a look at the downtick in short interest. The stock experienced a fall in short interest between September 29, 2017 and October 13, 2017 of -5.08%. Short shares fell 344,820 over that period. With short interest at 6,437,088 and short average daily volume at 1,826,173, the short-interest ratio is 4.0 and the percentage of shorted shares was 0.02% on October 13.
Several ratings analysts have issued ratings on the company. On July 26 Citigroup kept the company rating at “Buy” but moved up the price target to $290.00 from $285.00. On September 20 the company was downgraded from “Overweight” to “Equal-Weight” in an announcement from Morgan Stanley.
September 26 investment analysts at Credit Suisse maintained a stock rating of “Outperform” but lowered the price expectation from $327.00 to $266.00. October 17 investment analysts at Credit Suisse made no change to the company rating of “Outperform” but lowered the price target to $243.00 from $266.00.
On October 18 the stock rating was downgraded to “Outperform” from “Sell” and a price target of $243.00 was set by analysts at Edward Jones. October 19 investment analysts at Citigroup held the company rating at “Buy” and lowered the price expectation to $240.00 from $290.00.